Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VXB-213
- Development stage
- Phase 2
- Lead developer
- Vicebio
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
VXB-213 is a monovalent protein subunit vaccine candidate developed by Vicebio for the prevention of respiratory syncytial virus (RSV) infection. The vaccine utilizes proprietary Molecular Clamp technology, which is designed to lock viral fusion proteins into their native, pre-fusion trimeric conformation. This stabilization is critical for exposing key epitopes that elicit high titers of neutralizing antibodies. VXB-213 is being evaluated in clinical trials both as a standalone monovalent vaccine and as a comparator component for multivalent candidates, including the bivalent VXB-241 (RSV/hMPV) and the trivalent VXB-251 (RSV/hMPV/PIV3). It is administered via intramuscular injection and is primarily targeted at older adults.
- Other names
- monovalent respiratory syncytial virus vaccine
02
Targets
RSV F (Respiratory syncytial virus fusion protein)
Beyond the preview
Go deeper on VXB-213.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VXB-213.